Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Affimed (GB:0HL9)
LSE:0HL9
Affimed (0HL9) Share Price & Analysis
0 Followers
0HL9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.83 - $10.91
Previous Close$5.34
Volume100.00
Average Volume (3M)768.00
Market Cap
$79.64M
Enterprise Value$23.69M
Total Cash (Recent Filing)€72.05M
Total Debt (Recent Filing)€19.35M
Price to Earnings (P/E)N/A
Beta2.61
Next Earnings
May 22, 2024EPS Estimate
-$1.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,227,463
10 Day Avg. Volume911
30 Day Avg. Volume768
Standard Deviation0.37
R-Squared0.05
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)1.42
Price to Sales (P/S)10.86
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.00Price Target Upside181.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Affimed News
PremiumCompany Announcements
Affimed Therapeutics’ Optimistic Clinical Outlook
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe combination showed a favorable safety profile, with no cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft versus host disease reported.
Drug Development ProgressFirst AFM24 plus atezolizumab results expected could help demonstrate whether the combination therapy is able to co-activate the innate and adaptive immune systems for synergistic activity.
Regulatory MilestoneFDA Meeting Clears Way for Acimtamig + AB-101.
Bears Say
Clinical Trial OutcomesSkepticism grows around the potential of IO combinations without chemotherapy or targeted agents in anti-PD-(L)1 refractory settings, potentially impacting future stock performance.
Financial PerformanceDespite beating consensus estimates on net loss per share, the company's financial losses may continue to weigh on investor sentiment.
Market ReactionThe stock's significant drop reflects investor concerns over the lack of improved average durability of benefit, casting doubts on the company's competitive edge.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
0HL9 FAQ
What was Affimed’s price range in the past 12 months?
Affimed lowest share price was $2.83 and its highest was $10.91 in the past 12 months.
What is Affimed’s market cap?
Currently, no data Available
When is Affimed’s upcoming earnings report date?
Affimed’s upcoming earnings report date is May 22, 2024 which is in 33 days.
How were Affimed’s earnings last quarter?
Affimed released its earnings results on Mar 28, 2024. The company reported -$1.476 earnings per share for the quarter, beating the consensus estimate of -$1.636 by $0.16.
Is Affimed overvalued?
According to Wall Street analysts Affimed’s price is currently Undervalued.
Does Affimed pay dividends?
Affimed does not currently pay dividends.
What is Affimed’s EPS estimate?
Affimed’s EPS estimate is -$1.65.
How many shares outstanding does Affimed have?
Currently, no data Available
What happened to Affimed’s price movement after its last earnings report?
Affimed reported an EPS of -$1.476 in its last earnings report, beating expectations of -$1.636. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Affimed?
Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at N/A.
---
Affimed Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (181.16% Upside)
$15.00 (181.16% Upside)
Blogger Sentiment
Bullish
GB:0HL9 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-36.00%
12-Months-Change
Fundamentals
Return on Equity
-100.88%
Trailing 12-Months
Asset Growth
-49.85%
Trailing 12-Months
Company Description
Affimed
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
---
0HL9 Company Deck
---
0HL9 Earnings Call
Q4 2024
0:00 / 0:00
---
0HL9 Stock 12 Months Forecast
Average Price Target
$15.00
▲(181.16% Upside)
Technical Analysis
Affimed
―
Aldeyra Therapeutics
―
Alpine Immune Sciences
―
ANI Pharmaceuticals
―
Aurinia Pharmaceuticals
―
Best Analysts Covering 0HL9
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-16.31%
reiterated a buy rating 19 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -16.31% per trade.
---